



## Company Overview

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company's development portfolio features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.

## Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 14 2025, 7:30 AM EDT

## Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1 2025, 7:30 AM EDT

## ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 15 2025, 7:30 AM EDT

## Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	352.8m
Last Price	\$6.88
52-Week	\$3.9328 - \$7.5401

08/28/2025 08:00 PM EDT

## Investor Relations

[ir@abeonatherapeutics.com](mailto:ir@abeonatherapeutics.com)

## Management Team

### Vishwas Seshadri, Ph.D., M.B.A.

Chief Executive Officer, Director

### Alison Hardgrove, J.D., M.B.A

Chief People Officer

### Brian Kevany, Ph.D.

Senior Vice President, Chief Technical Officer & Chief Scientific Officer

### Brendan O'Malley, J.D., Ph.D.

Chief Legal Officer

### Madhav Vasanthavada, Ph.D., M.B.A.

Senior Vice President, Chief Commercial Officer & Head of Business Development

### Joseph Vazzano

Chief Financial Officer

### Megan Callan

Vice President, Head of Quality

### Carl Denny

Senior Vice President, Regulatory Affairs

### Greg Gin

Vice President, Investor Relations and Corporate Communications

### Amanda Moore, MSHS

Vice President, Program Leadership and Clinical Operations

## Abeona Therapeutics Inc.

6555 Carnegie Avenue  
4th Floor  
Cleveland, OH 44103

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.